SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-19-008673
Filing Date
2019-05-15
Accepted
2019-05-15 07:51:01
Documents
5
Period of Report
2019-05-15

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT OF FOREIGN ISSUER f6k051519_biondvax.htm 6-K 11136
2 BIONDVAX PHARMACEUTICALS LTD. LETTER TO ITS SHAREHOLDERS FROM CEO DR. RON BABECO f6k051519ex99-1_biondvax.htm EX-99.1 26070
3 GRAPHIC image_001.jpg GRAPHIC 7555
4 GRAPHIC image_002.jpg GRAPHIC 49732
5 GRAPHIC image_003.jpg GRAPHIC 3871
  Complete submission text file 0001213900-19-008673.txt   117382
Mailing Address 14 EINSTEIN ST. NES-ZIONA L3 74036
Business Address 14 EINSTEIN ST. NES-ZIONA L3 74036 972-8-9302529
BiondVax Pharmaceuticals Ltd. (Filer) CIK: 0001611747 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-37353 | Film No.: 19825117
SIC: 2836 Biological Products, (No Diagnostic Substances)